dc.contributorCruz, Ivana Beatrice Mânica da
dc.contributorhttp://lattes.cnpq.br/3426369324110716
dc.contributorRubin, Maribel Antonello
dc.contributorhttp://lattes.cnpq.br/7237734243628134
dc.contributorSouza Filho, Olmiro Cezimbra de
dc.contributorhttp://lattes.cnpq.br/5123716272383615
dc.creatorDuarte, Thiago
dc.date.accessioned2019-07-10T22:30:39Z
dc.date.accessioned2022-10-07T22:43:29Z
dc.date.available2019-07-10T22:30:39Z
dc.date.available2022-10-07T22:43:29Z
dc.date.created2019-07-10T22:30:39Z
dc.date.issued2015-02-27
dc.identifierhttp://repositorio.ufsm.br/handle/1/17402
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4038129
dc.description.abstractRosuvastatin is used as a drug of first choice in treating hypercholesterolemia due to competitive inhibition of HMG-CoA reductase enzyme which converts HMG-CoA to mevalonic acid which is the rate-limiting step in cholesterol synthesis, also attenuates the inflammatory process and oxidative, mainly by reducing the production of superoxide anion. Superoxide anion is metabolized by manganese-dependent superoxide dismutase (MnSOD or SOD2) that act into mitochondria. In humans, there is a gene polymorphism where a valine (Val) to alanine (Ala) substitution occurs at the 16th amino acid (Ala16Val-SOD2). This polymorphism having two alleles A and V, resulting in three possible genotypes: AA, AV and VV. The VV genotype has been associated with the risk of developing several metabolic diseases, such as hypercholesterolemia. Thus, in order to further explore this phenomenon , this study investigated the influence of Ala16Val - SOD2 polymorphism on lipid profile and inflammatory and fibrinolytic biomarkers of 122 hypercholesterolemic patients treated with 20 mg of rosuvastatin for 120 days. The results indicated that patients with the VV genotype showed a lower response to rosuvastatin, compared with patients with the AA and AV genotypes. The effects of rosuvastatin in inflammatory and fibrinolytic biomarkers were also milder in these patients. These results suggest some effects of pharmacogenetic - SOD2 Ala16Val polymorphism in the treatment of hypercholesterolemia.
dc.publisherUniversidade Federal de Santa Maria
dc.publisherBrasil
dc.publisherFarmacologia
dc.publisherUFSM
dc.publisherPrograma de Pós-Graduação em Farmacologia
dc.publisherCentro de Ciências da Saúde
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.subjectHipercolesterolemia
dc.subjectInflamação
dc.subjectCoagulação
dc.subjectPolimorfismo MTS-SOD2
dc.subjectRosuvastatina
dc.subjectFarmacogenética
dc.subjectHypercholesterolemia
dc.subjectInflammation
dc.subjectCoagulation
dc.subjectMTS-SOD2 polymorphism
dc.subjectRosuvastatin
dc.subjectPharmacogenetics
dc.titleEfeito farmacogenético do polimorfismo Ala16Val do gene da MnSOD na resposta de pacientes hipercolesterolêmicos a rosuvastatina
dc.typeDissertação


Este ítem pertenece a la siguiente institución